Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

offering a potential novel avenue for treatment. "We are thrilled to have our first participant enrolled," said Chief Executive Officer Cheri Ackerman. "For the millions of people who suffer from ...

While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

It is not just about itchy skin: Know surprising truth about Atopic Dermatitis as Eczema is on the rise in ... has led to the development of targeted treatments, offering help for individuals ...

When it comes to medical marketing, some campaigns are built around celebrity spokespeople while others opt for first-person ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.